Success Metrics

Active Trials

4(80%)

Phase Distribution

Ph phase_1

60%

Ph phase_3

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Detailed Status

Recruiting3

Not yet recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 13 (60.0%)

Phase 32 (40.0%)

Trials by Status

not_yet_recruiting120%

recruiting360%

active_not_recruiting120%

Recent Activity

4 active trials

Showing 5 of 5

recruitingphase_1

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560

recruitingphase_3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222

active_not_recruitingphase_1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903

recruitingphase_1

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

NCT07295951

not_yet_recruitingphase_3

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

NCT07223814

Clinical Trials (5)

Showing 5 of 5 trials

NCT04811560Phase 1

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Recruiting

NCT06852222Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Recruiting

NCT05453903Phase 1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Active Not Recruiting

NCT07295951Phase 1

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

Recruiting

NCT07223814Phase 3

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5